Clinical trial NCT01656252: Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
Official title: Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults With Acute Myeloid Leukemia (AML) in Complete Remission
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
Keywords: Acute Leukemia
Complete Remission
Consolidation
Consolidation Chemotherapy
Cytarabine
Eltrombopag
Leukemia
Thrombocytopenia
Thrombopoietin
Lead sponsor: PrECOG, LLC.
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
name: Novartis
First posted: 2012-08-02
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with Acute Myeloid Leukemia (AML) in complete remission will receive eltrombopag while undergoing consolidation chemotherapy with high-dose cytarabine. Eltrombopag may help increase the number of platelets during chemotherapy and may help prevent the risk of bleeding.

Phase I will study the side effects, best dose and platelet effects of eltrombopag when given with consolidation chemotherapy. After the maximum safe and tolerated dose and schedule is found in Phase I, the study will proceed to Phase II. Phase II will confirm the dose and schedule of eltrombopag identified in Phase I that can increase platelet counts in patients receiving consolidation therapy.

Detailed description: Consolidation chemotherapy with high dose cytarabine usually causes myelosuppression for 14 to 21 days after each treatment. Patients have low blood counts for days or weeks before the bone marrow resumes function. This may result in e.g., hospitalization, treatment with antibiotics, and transfusions with blood and/or platelets. In addition, this may cause a delay in treatment and reduction in dose. To achieve the best outcome from treatment, dose reductions and delays in treatment must be avoided.

The incidence and duration of decreased white blood cells (neutropenia) and neutropenic complications have been reduced by the use of growth colony stimulating factors. Additionally, the use of erythropoietin-stimulating factors has reduced anemia and the need for red blood cell transfusions. Thrombocytopenia remains an important limiting factor in administration of chemotherapy and maintaining dose intensity in some patients. Additionally, the risk of bleeding secondary to low platelet counts may increase sickness or even death in patients undergoing cancer treatment.

Thrombopoietin (TPO) is the principal cytokine involved in the regulation of megakaryopoiesis and platelet production. Eltrombopag is an orally bioavailable, small molecule, TPO-receptor agonist that stimulates platelet production by a similar, but not identical, mechanism to endogenous TPO. Eltrombopag has been approved in the U.S. for the treatment of chronic Idiopathic Thrombocytopenic Purpura. Eltrombopag is also under development for other indications such as Hepatitis C Virus-associated thrombocytopenia, Myelodysplastic Syndrome/AML, and oncology related thrombocytopenias. This agent appears to possess many of the desirable properties for a treatment for chemotherapy induced thrombocytopenia, including oral administration.

The Phase I portion of this study will be conducted using a dose escalation/de-escalation strategy for patients in either the first or second complete remission. Dose escalations are planned in the form of both acceleration of date of initiation of eltrombopag relative to the start of consolidation chemotherapy as well as increasing daily dosing.

The Phase II portion will be conducted using the dose and schedule selected from the Phase I portion of the study for those patients in first complete remission. Patients will be used as their own controls, e.g., a two-period two-treatment cross-over design. Patients will be randomly allocated 1:1 to one of two sequences. Patients randomized to Sequence A will receive eltrombopag with their first cycle of consolidation and placebo with Cycle 2. Patients randomized to Sequence B will receive placebo with their first cycle of consolidation and eltrombopag with Cycle 2. The treatment assignment will be blinded to the patient and all study/sponsor personnel.

Patients will undergo blood sample collection for Thrombopoietin(TPO)/ Erythropoietin(EPO) and pharmacokinetic analysis of eltrombopag in Phase I and pharmacokinetic analysis of eltrombopag in the Phase II portion of the study.

Eligibility criteria: Inclusion Criteria:

• Cytomorphologically documented diagnosis of acute myeloid leukemia (AML). Acute promyelocytic leukemia patients will be excluded (FAB M3). FAB classification, cytogenetics and molecular markers (if applicable) must be available at registration.

Phase I Enrollment:

* Must be in first or second complete remission, e.g., no evidence of active disease in blood, bone marrow (\<5% blasts), or other tissues.
* For each remission, may have received no more than 2 cycles of induction treatment (any type).
* May have received no more than one course of consolidation for the current remission prior to enrollment (any type)

Phase II Enrollment:

* Must be in first complete remission, e.g., no evidence of active disease in blood, bone marrow (\<5% blasts), or other tissues.
* May have received no more than 2 cycles of induction treatment (any type).

Enrollment in Either Phase:

* Remission status must be documented by a bone marrow examination up to 28 days prior to study registration.
* Have recovered from induction and first consolidation (if applicable) therapy side effects (or ≤grade 1).
* ≥18 years of age and ≤70 years of age.
* ECOG performance status 0, 1, 2.
* Have not received cytotoxic drug therapy within 21 days of registration.
* Have not received hematopoietic colony stimulating growth factors within 14 days of registration.
* Have not received packed red blood cells or platelets within 7 days of registration.
* Have not received investigational agents within 30 days of registration and will not receive any investigational agents other than eltrombopag/placebo during study.
* Signed IRB-approved informed consent.
* Willing to provide blood samples for research purposes.
* Adequate organ function obtained within 28 days prior to registration:

  * Absolute neutrophil count \>1 x 10⁹/L
  * Platelet count \>100 x 10⁹/L
  * Total direct serum bilirubin ≤1.5x upper limit of normal (ULN)
  * ALT and AST ≤3x ULN
  * BUN and serum creatinine \<2x ULN
  * Albumin ≥2.5 g/dL
  * PT and PTT 80-120% of institutional normal range
* Women of childbearing potential must have a negative serum pregnancy test within 14 days of registration.
* Not pregnant nor breast feeding.
* Women of childbearing potential and sexually active males must use an accepted and effective method of contraception.
* Patients of known East Asian ancestry (Chinese, Japanese, Taiwanese, and Korean) are excluded from protocol participation for safety and efficacy reasons.
* Able to swallow and retain orally administered medication.
* No clinically significant gastrointestinal abnormalities such as malabsorption syndrome or major resection of the stomach or bowels.
* No clinical evidence of hepatomegaly or splenomegaly.
* No known risk for Torsades de Pointes. (Eltrombopag use has not been shown to be associated with Torsades de Pointes.)
* No active or unresolved infection and must be off all antibiotics for at least 7 days prior to registration.
* No current evidence of invasive fungal infection.
* No known Hepatitis B, Hepatitis C active disease.
* No known Human Immunodeficiency Virus (HIV) seropositivity. The risk for potential toxicities secondary to HIV (e.g., increased risk for fatal opportunistic infection) may confound the toxicity profile of eltrombopag.
* Patients with a history of Central Nervous System (CNS) leukemia are eligible if there is documentation of no current CNS involvement on cerebrospinal fluid (CSF) examination (e.g., negative CSF by lumbar puncture) within 28 days of registration.
* No prior or concomitant malignancy in the past 5 years which is currently active and likely to interfere with the patient's treatment for AML or which is likely to increase the patient's morbidity or mortality. No prior chemotherapy or radiation therapy allowed (unless related to AML treatment).
* No concurrent organ damage or medical problems that would prohibit therapy.

Primary outcomes:
measure: Phase I- Optimal Tolerated Dose of Eltrombopag
timeFrame: 13 months
measure: Phase I - Dose Level With Best Kinetics of Platelet Count Recovery
timeFrame: 13 months
measure: Phase II- Assess if Platelet Count Recovery is Increased With Eltrombopag
timeFrame: 62 months
Secondary outcomes:
measure: Phase I & Phase II- Pharmacokinetics of Eltrombopag
timeFrame: 62 months
measure: Phase II- Platelet Transfusion Requirements
timeFrame: 62 months
measure: Phase II- Red Blood Cell Transfusion Requirements
timeFrame: 62 months
measure: Phase II- Bleeding Event Occurrence
timeFrame: 62 months
measure: Phase II- Time to Platelet Count Recovery
timeFrame: 62 months
measure: Phase II- Depth of Platelet Nadir
timeFrame: 62 months
measure: Phase II- Duration of Platelet Nadir
timeFrame: 62 months
measure: Phase II- Safety of Eltrombopag With Consolidation
timeFrame: 62 months
Other outcomes:
measure: Exploratory- Eltrombopag Effect on TPO/EPO
timeFrame: 62 months
Locations:
city: Worcester
country: United States
facility: University of Massachusetts Worcester
state: Massachusetts
city: Rochester
country: United States
facility: Mayo Clinic, Rochester
state: Minnesota
city: Cleveland
country: United States
facility: University Hospitals Case Medical Center
state: Ohio
city: Hershey
country: United States
facility: Penn State Hershey Cancer Institute
state: Pennsylvania
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: University Hospitals Cleveland Medical Center
name: Hillard M Lazarus, MD
role: STUDY_CHAIR
References:
citation: Mavroudi I, Pyrovolaki K, Pavlaki K, Kozana A, Psyllaki M, Kalpadakis C, Pontikoglou C, Papadaki HA. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res. 2011 Mar;35(3):323-8. doi: 10.1016/j.leukres.2010.06.029. Epub 2010 Aug 4.
citation: Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009 Oct 29;114(18):3899-908. doi: 10.1182/blood-2009-04-219493. Epub 2009 Aug 26.
citation: Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Mostafa Kamel Y. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010 Oct;26(10):2339-46. doi: 10.1185/03007995.2010.510051.
citation: Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009 Jan;46(1 Suppl 2):S26-32. doi: 10.1053/j.seminhematol.2008.12.007.
citation: Strickland SA, Wang XV, Cerny J, Rowe JM, Rybka W, Tallman MS, Litzow M, Lazarus HM. A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. Leuk Lymphoma. 2020 Sep;61(9):2191-2199. doi: 10.1080/10428194.2020.1762878. Epub 2020 May 30.